References (continued)
20. ByrneCM,ThompsonJF,JohnstonH,etal.Treatmentofmetastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res. 2005;15(1):45-51.
Continue Reading
21. Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet. 1979;149(1):17-21.
22. Rodríguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, et al. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res. 2001;32(4):273-276.
23. Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22(7):2135-2142.
24. Richards J, Thompson J, Atkins MB et al. A controlled, randomized Phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol. 2002;21.
25. Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther. 2008;8(6):839-44.
26. StopeckAT,HershEM,AkporiayeET,etal.PhaseIstudyofdirect gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol. 1997;15(1):341-349.
27. GonzalezR,HutchinsL,NemunaitisJ,etal.Phase2trialofallovectin-7 in advanced metastatic melanoma. Melanoma Res. 2006;16(6):521-526. 28. Karakousis CP, Douglass HO Jr, Yeracaris PM, et al. BCG immunotherapy in patients with malignant melanoma. Arch Surg. 1976;111(6):716-718. 29. SeiglerHF,ShingletonWW,PickrellKL.IntralesionalBCG,intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma: a clinical assessment. Plast Reconstr
Surg. 1975;55(3):294-298.
30. Robinson JC. Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol. 1977;9(6):587-593.
31. Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer. 1998;77(12):2336-2342.
32. Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer. 1998;83(1):148-157.
33. Marty M, Garbay JR, Gehl J, et al. Electrochemotherapy an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl. 2006;4(11):3-13.
34. Ridolfi L, Ridolfi R, Ascari-Raccagni A, et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol. 2001;15(3):218-223.
35. Agarwala SS. Intralesional therapy for advanced melanoma: promise and limitation. Curr Opin Oncol. 2015;27(2):151-156.
36. Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol. 2011;104(7):711-717.
37. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional rose bengal. Melanoma Res. 2008;18(6):405-411.
38. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763-5771.
39. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780-2788.
40. Puzanov MM, Andtbacka RH, Minor DR, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 2014;32(5 suppl):9029.
41. Kidner TB, Morton DL, Lee DJ, et al. Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother. 2012;35(9):716-720.
42. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A. 1996;93(26):15388-15393.
43. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNAliposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993;90(23):11307-11311.
44. Plautz GE, Yang ZY, Wu BY, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A. 1993;90(10):4645-4649.
45. Cohen MH, Elin RJ, Cohen BJ. Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guerin therapy for locally metastatic melanoma. Cancer Immunol Immunother. 1991;32(5):315-324.
46. Mali B, Jarm T, Snoj M, et al. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013;39(1):4-16.
47. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718-730.
48. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GMCSF. Melanoma Res. 1996;6(3):247-255.
49. Adler A, Stein JA, Kedar E, et al. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod. 1984;3(5):491-500.
50. EklundJW,KuzelTM.Areviewofrecentfindingsinvolvinginterleukin-2-based cancer therapy. Curr Opin Oncol. 2004;16(6):542-546.
51. Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother. 1992;46(10):473-484.
52. McDermottD,LebbeC,HodiFS,etal.Durablebenefitandthepotential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40(9):1056-1064.
53. ByersBA,Temple-OberleCF,HurdleV,etal.Treatmentofin-transit melanoma with intra-lesional interleukin-2: a systematic review. J Surg Oncol. 2014;110(6):770 -775.
54. Tartour E, Mehtali M, Sastre-Garau X, et al. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer. 2000;83(11):1454-1461.
55. Green DS, Dalgleish AG, Belonwu N, et al. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol. 2008;159(3):606-614.
56. Dummer R, Rochlitz C, Velu T, et al. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Molec Ther. 2008;16(5):985-994.
57. Garcia MS, Ono Y, Martinez SR, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res. 2011;21(3):235-243.
58. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer. 2003;89(9):1620-1626.
59. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, et al. Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2. [In Spanish]. Act Dermosifiliogr. 2009;100(7):571-585.
60. Tan CY, Neuhaus SJ. Novel use of rose bengal (PV-10) in two cases of refractory scalp sarcoma. ANZ J Surg. 2013;83(1-2):93.
61. Foote MC, Burmeister BH, Thomas J, et al. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res. 2010;20(1):48-51.
62. Toomey P, Kodumudi K, Weber A, et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PloS One. 2013;8(7):e68561.
63. US Food and Drug Administration. FDA approves first-ofits-kind product for the treatment of melanoma. http://www.fda.gov /NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm. Accessed January 22, 2016.
64. NemunaitisJ.Oncolyticviruses.InvestNewDrugs.1999;17(4):375-386. 65. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nature Rev Microbiol. 2014;12(1):23-34.
66. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292-303.
67. Damian DL, Shannon KF, Saw RP, Thompson JF. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol. 2009;50(4):266-271.
68. Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol. 2007;56(5):869-871.
69. Damian DL, Thompson JF. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg. Am J Clin Dermatol. 2011;12(6):403-404.
70. Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol. 2014;109(4):308-313.
71. Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol. 2001;145(3):385-405.
72. van der Steen PH, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin. 1993;11(3):619-622.
73. National Cancer Institute. FDA approval for imiquimod. http://www.cancer.gov/about-cancer/treatment/drugs/fda-imiquimod. Accessed January 22, 2016.
74. QuigleyEA,HalpernAC.Microinvasivemelanoma:cutaneouspharmacotherapeutic approaches. Am J Clin Dermatol. 2013;14(2):125-137.
75. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Expert Dermatol. 2004;29(1):15-21.
76. Shistik G, Prakash AV, Fenske NA, et al. Treatment of locally metastatic melanoma: a novel approach. J Drug Dermatol. 2007;6(8):830-832. 77. Florin V, Desmedt E, Vercambre-Darras S, et al. Topical treatment
of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs. 2012;30(4):1641-1645.
78. Junkins-Hopkins JM. Imiquimod use in the treatment of lentigo maligna. J Am Acad Dermatol. 2009;61(5):865-867.
Source: Cancer Control
Originally published January, 2016.
